Background: Hemolytic anemia (HA) is a group of diseases characterized by the accelerated destruction of red blood cells (RBCs), resulting in various clinical manifestations such as anemia and jaundice. Objective: This study aimed to investigate the ameliorative effects of Myricetin on phenylhydrazine (PHZ)-induced hemolytic anemia in adult male rats. Methodology: Forty rats were randomly divided into four groups. Group I received normal saline orally. Group II consisted of anemic rats administered normal saline orally. Group III included anemic rats treated with Myricetin (1 mg/kg body weight, i.p, once daily), and Group IV comprised anemic rats treated with folic acid (1 mg/kg body weight, orally, once daily). All treatments were continued for 30 consecutive days. Serum samples were collected on days 7, 15, and 30 and analyzed using biochemistry analyzer to assess hematological, inflammatory biomarkers. Results: The results showed a significant, time-dependent improvement in key hematological and inflammatory parameters, including Ferritin, Serum Iron, Lactate dehydrogenase (LDH), C-Reactive Protein (CRP), and Indirect bilirubin Conclusion: Collectively, these findings suggest that Myricetin may exerts antioxidant, anti-inflammatory, that contribute to hematological improvement. This highlights its potential as a natural therapeutic candidate for the management of hemolytic anemia.